ALC.SW Alcon (SIX) closes CHF60.08 10 Feb 2026: heavy volume ahead of earnings

ALC.SW stock closed at CHF60.08 on 10 Feb 2026 after a busy session on the SIX exchange, marking a -1.09% intraday move on volume 917,001 shares. Trading activity made Alcon Inc. one of the most active Swiss healthcare names today, with price action concentrated near the session low CHF59.88. Investors are positioning ahead of the company earnings report scheduled for 24 Feb 2026, and short-term flows have nudged the stock below its 50-day average CHF63.30, highlighting heightened near-term risk and opportunity.

Market action and why ALC.SW stock was most active today

Alcon (ALC.SW) topped active lists on the SIX with 917,001 shares traded, near but below its average volume 1,149,118. The stock opened at CHF61.02, hit a high of CHF61.14, and closed at CHF60.08, showing intraday pressure. One clear claim: heavy trading reflects positioning into the upcoming earnings announcement on 24 Feb 2026 and dealer inventory adjustments.

Valuation snapshot and financial ratios for ALC.SW stock

Alcon trades at PE 36.86 with EPS CHF1.63, a price-to-book near 1.75, and market capitalisation about CHF29.72 billion. The company shows a healthy current ratio 2.12 and net debt to EBITDA 1.82, which supports solvency claims. Compared with healthcare peers, Alcon’s PE sits above the sector average ~34.73, suggesting premium pricing on growth and margin resilience.

Technical read: short-term signals for ALC.SW stock

Technical indicators show mixed momentum: RSI 58.62 and MACD histogram 0.03 point to neutral momentum, while ADX 14.16 shows no clear trend. The 50-day average is CHF63.30 and the 200-day average is CHF66.18, so the share price is below key moving averages. Traders should note ATR CHF1.10 as an intraday volatility gauge and Bollinger middle band at CHF63.72 as a resistance marker.

Fundamentals and growth drivers behind ALC.SW stock

Alcon’s two segments — Surgical and Vision Care — drive steady cash flow, with revenue per share CHF20.65 and free cash flow per share CHF3.22. Recent growth: operating cash flow rose 49.64% year-over-year and free cash flow growth improved materially. The business shows operating margin 14.16% and return on equity 4.77%, which supports claims of operational improvement though ROE remains modest versus some peers.

Risks, catalysts and sector context for ALC.SW stock

Key risks include slower procedure volumes in surgical markets and margin pressure from pricing dynamics. Catalysts include the 24 Feb 2026 earnings release and product cycle upgrades in IOLs and vision-care consumables. In the Healthcare sector, average PE is 34.73; Alcon trades slightly richer, reflecting a mix of steady cash flow and exposure to elective surgery cycles.

Meyka AI grade and model forecast for ALC.SW stock

Meyka AI rates ALC.SW with a score of 74.99 out of 100 — Grade B+ (BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of CHF58.39, versus the current price CHF60.08, implying an expected downside of -2.79%. Forecasts are model-based projections and not guarantees.

Final Thoughts

ALC.SW stock finished the session at CHF60.08, with high trading activity and a total of 917,001 shares changing hands, underlining why it was one of the most active names on the SIX today. From a valuation angle the stock is premium to some healthcare peers on PE 36.86 but supported by improving cash flow metrics and a strong current ratio 2.12. Technically, the share sits below its 50-day average CHF63.30, so near-term momentum favors cautious traders ahead of the 24 Feb 2026 earnings report. Meyka AI’s forecast gives a one-year model value of CHF58.39, implying -2.79% from today’s close; this suggests limited upside in the immediate 12-month model while shorter-term catalysts like procedure volume trends could swing performance. For most active traders, watch intraday range and volume spikes around news events; for investors, track earnings and margin cadence against the company’s guidance. Meyka AI, our AI-powered market analysis platform, flags both opportunity and risk and recommends confirming positions with your own research. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.